Financial Updates ResMed exited the second quarter of fiscal 2022 with cash and cash equivalents of $194.5 million compared with $276.1 million at the end of the fiscal first quarter. Total debt (short and long-term) at the end of the fiscal second quarter was $679.9 million compared with $655.4 million a year ago. Cumulative net cash used in operating activities at the end of the fiscal second quarter was $154.2 million compared with cumulative net cash inflow of $313.9 million in the year-ago quarter. The company paid out $61.2 million as dividends in the fiscal second quarter. Our Take ResMed's earnings met the Zacks Consensus Estimate in the fiscal second quarter and increased year over year. The company saw increased demand for sleep and respiratory care devices on steady recovery of markets from COVID-19 impacts and a competitor's product recall.